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Background: Effective policies to control hypertension require an understanding of its distribution in the population
and the barriers people face along the pathway from detection through to treatment and control. One key factor is
household wealth, which may enable or limit a household’s ability to access health care services and adequately
control such a chronic condition. This study aims to describe the scale and patterns of wealth-related inequalities in
the awareness, treatment and control of hypertension in 21 countries using baseline data from the Prospective Urban
and Rural Epidemiology study.
Methods: A cross-section of 163,397 adults aged 35 to 70 years were recruited from 661 urban and rural
communities in selected low-, middle- and high-income countries (complete data for this analysis from 151,619
participants). Using blood pressure measurements, self-reported health and household data, concentration indices
adjusted for age, sex and urban-rural location, we estimate the magnitude of wealth-related inequalities in the
levels of hypertension awareness, treatment, and control in each of the 21 country samples.
Results: Overall, the magnitude of wealth-related inequalities in hypertension awareness, treatment, and control was
observed to be higher in poorer than in richer countries. In poorer countries, levels of hypertension awareness and
treatment tended to be higher among wealthier households; while a similar pro-rich distribution was observed for
hypertension control in countries at all levels of economic development. In some countries, hypertension awareness
was greater among the poor (Sweden, Argentina, Poland), as was treatment (Sweden, Poland) and control (Sweden).
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Conclusion: Inequality in hypertension management outcomes decreased as countries became richer, but the
considerable variation in patterns of wealth-related inequality - even among countries at similar levels of economic
development - underscores the importance of health systems in improving hypertension management for all.
These findings show that some, but not all, countries, including those with limited resources, have been able to
achieve more equitable management of hypertension; and strategies must be tailored to national contexts to
achieve optimal impact at population level.
Keywords: Global health, Hypertension, Socioeconomic factors, Healthcare disparitiesBackground
In 2013 the World Health Organization (WHO) published
its Global Action Plan for the Prevention and Control of
Non-Communicable Diseases (NCDs), with one of nine
voluntary targets to reduce preventable deaths from
cardiovascular diseases (CVD) through increased use of
secondary prevention measures and improvements in
hypertension control [1]. The Sustainable Development
Goals have subsequently reinforced the need to tackle
NCDs, but there are many barriers to be overcome [2].
One such barrier is a lack of understanding of the
scale and nature of the gaps in care, all along the path-
way from early detection of hypertension to treatment
and control, including differences among population
groups within individual countries. Among the many
studies on hypertension management, only a minority
examine the entire pathway, and even fewer examine
inequalities at each stage. Among those that do, the ma-
jority are from high-income country settings. The Pro-
spective Urban Rural Epidemiology (PURE) study, a
large multi-country longitudinal study of NCD risk fac-
tors and outcomes, has revealed marked differences in
hypertension prevalence, awareness, treatment and con-
trol by age, gender, and education level in countries at
all income levels, and between urban and rural locations
[3]. Yet, other than this and a few other exceptions [4–6],
comparative studies of inequalities in the treatment and
control of hypertension are sparse.
Those studies that exist have largely focused on educa-
tion and ethnicity as measures of socio-economic status
(SES) yet a comprehensive understanding also requires
information on measures more directly related to con-
temporary economic status, such as household income
and wealth. Such measures more directly reflect a
household’s command over its resources and thus, po-
tentially, the ability to obtain health care. Studies that
have examined inequalities in hypertension awareness,
treatment or control associated with household income
or wealth have typically done so by comparing outcomes
across wealth quintiles. In one multi-country study, for
example, those from richer households in China, Ghana,
India, Mexico, Russia and South Africa tended to be
more likely to have their hypertension controlled [5];however, the magnitude of this inequality cannot be easily
quantified or summarized using this approach, or com-
pared across countries.
In this paper we undertake further analysis of data
from the PURE study and go beyond our earlier work in
two ways: first by characterizing the scale of wealth-
related inequalities in hypertension awareness, treatment
and control using a summary measure that can reliably
be compared across countries and outcomes; and sec-
ond, by examining 21 individual countries rather than
groups of countries at different levels of development.
Methods
Study design and participants
This cross-sectional analysis uses baseline data from
individuals enrolled in the PURE cohort study, which
seeks to determine the relationship between the burden
of NCDs and a range of individual, household, and com-
munity characteristics. Its methods have been described
elsewhere [7, 8]. Briefly, participants were recruited from
communities in 21 countries, purposefully selected to
capture wide variation in sociocultural diversity and
economic development, as defined by the World Bank
in 2006 [9]. Low-income countries include Bangladesh,
India, Pakistan, Tanzania, and Zimbabwe; lower middle-
income countries include China, Colombia, Iran, Occu-
pied Palestinian Territory (OPT), and the Philippines;
upper middle-income countries include Argentina, Brazil,
Chile, Malaysia, Poland, South Africa, and Turkey; and
high-income countries were Canada, Saudi Arabia,
Sweden and the United Arab Emirates (UAE). The timing
of data collection in each country is shown in Additional
file 1.
Within each country, participants were selected from
communities in both rural and urban areas. Communi-
ties were defined as groups of people who reside within
a specific geographic area and who were generally ex-
pected to have similar characteristics (e.g. culture, socio-
economic status, use of amenities, goods, and services).
Existing administrative boundaries, such as village limits
or postal code areas, or physical features (e.g. area
bounded by selected streets) were used to define urban
communities, while rural communities were defined as
Palafox et al. International Journal for Equity in Health  (2016) 15:199 Page 3 of 14villages or postal code areas located at least 50 km away
from an urban center. Within strata, communities were
drawn from areas of varying income levels. Sampling
within participating communities sought to recruit an
unbiased sample of households (Additional file 2 pro-
vides supplemental information on sampling).
Eligible households had at least one member aged 35
to 70 years intending to stay at that address for another
4 years. For practical reasons the goal was not to under-
take proportionate sampling, but rather, to show eco-
nomic and sociocultural diversity and include sites where
investigators were committed to collecting high-quality
data at a modest budget and following up participants
over a number of years. However, those included are
broadly comparable to the populations of the countries in
which they reside in terms of risk factors and mortality
(Additional file 3 provides supplemental information on
the characteristics of the PURE samples) [10, 11]. Eligible
participants between the ages of 35 and 70 years who pro-
vided written informed consent completed a standardized
questionnaire on medical history, individual- and
household-level risk factors, and underwent a basic phys-
ical examination as described in the INTERHEART study
[12] (Additional file 4 provides supplemental information
on these procedures). The PURE study was approved by
research ethics committees in the participating countries.
Measurement of health-related outcomes and participant
characteristics
Sitting blood pressure was measured twice by trained
research assistants following a standardized procedure
using an Omron digital blood pressure measuring device
(Omron HEM-757), as recommended by the WHO
STEPwise approach to Surveillance (STEPS) [13]. Subjects
listed all current prescription medications. This informa-
tion provided the proportion of participants with hyper-
tension who were aware of their condition and who were
receiving treatment. In the main analyses, control was the
proportion of participants with hypertension who had an
average systolic and diastolic blood pressure of less than
140/90 mm Hg, also as recommended by the WHO
STEPS protocol [13] and in many current guidelines [14].
We report three standard definitions of hypertensionTable 1 Definitions of hypertension
Standard lower
threshold definitiona
Subjects reported having been diagnosed with hypert
lowering medication, or if they had an average sitting
of at least 90 mm Hg, or both.
Alternative lower
threshold definition
Subjects reported having been diagnosed with hypert
medication, or if they had an average systolic blood p
Hg, or both.
Alternative ‘higher
threshold’ definition
Subjects reported having been diagnosed with hypert
lowering medication, or if they had an average blood
aThe paper reports three definitions to enable comparisons with other research. Ho
of these to define the denominator(Table 1) to enable comparisons with other research [15],
but use the standard ‘lower threshold’ definition to define
the denominator in the main analyses.
Following the Demographic and Health Surveys
(DHS), the questionnaire collected an extensive range of
socio-demographic data, including household posses-
sions: electricity supply, automobile, computer, televi-
sion, motorbike, livestock, fridge, other four-wheel
vehicle, washing machine, stereo, bicycle, kitchen mixer,
telephone, land/real estate and kitchen window [16].
Within each country, these were used to generate an
asset-based wealth index, based on that used in the DHS
and using principal components analysis, which places
surveyed households on a continuous scale of relative
wealth from poorest to richest [17]. This approach is de-
signed to permit meaningful comparisons of observed
inequalities across countries at different levels of devel-
opment [18]. The continuous score was divided into
country-specific wealth quintiles that reflect the distribu-
tion of household wealth within each of the country co-
horts. Additional file 5 provides further details on the
asset-based wealth index. Age was calculated in years
from date of birth, or self-reported age in years when
date of birth was unknown.
Analysis of wealth-related differences
For each country, we used the continuous household
wealth score to generate a summary measure of the de-
gree of wealth-related differences for each hypertension
outcome. We estimated the Wagstaff concentration
index indirectly standardized for age, gender and urban/
rural location derived using the convenient regression
approach to produce point estimates and 95% confi-
dence intervals corrected for within-cluster correlation
at community level obtained using the delta method
[19–21]. As the binary outcomes were coded as 0 for no
and 1 for yes, index values were normalized by dividing
by 1 minus the mean [22].
The value of the index ranges from –1 to 1, where a
negative value indicates a disproportionate concentra-
tion of the outcome among the poor, and a positive value
indicates a disproportionate concentration of the outcome
among the rich. The index is zero when there is no wealth-ension by a health care professional and receiving blood pressure-
systolic blood pressure of at least 140 mm Hg, diastolic blood pressure
ension by a health care professional or receiving blood pressure-lowering
ressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm
ension by a health care professional and receiving blood pressure-
pressure above the threshold of 160/100 mm Hg.
wever, the main analyses by hypertension management outcome use the first
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tive index means that the probability of having hyperten-
sion and being aware of it, or having it treated or
controlled, is higher among the rich (i.e. the outcomes are
‘pro-rich’). The magnitude of the concentration index can
be used to give a relative sense of the degree of inequality
in either direction (i.e. closer to 0 =more equal).
We present the concentration index as our core meas-
ure of relative wealth-related inequality; however, we
also illustrate absolute inequalities for each outcome in
two ways. Within each country, we used mixed-effects
logistic regression to analyze data on those with hyper-
tension, as defined above, and generated estimates of
three prevalence outcomes: being aware of one’s hyper-
tension diagnosis, being treated for hypertension, and
having controlled hypertension. Although basic logit
models without random effects produced a better fit in
some countries with few communities, the mixed-effects
model enabled us to apply a consistent approach, thus
enabling comparability. The estimates were adjusted for
age, gender, urban/rural location, and a random effect for
community. These were plotted by wealth quintile to show
the patterns at each stage of the treatment pathway, and theTable 2 Characteristics of PURE cohort, by country (ordered by 2006
2006 World Bank
country income group
Participa
Country No. of Communities Number
High income Canada 77 10412
Sweden 24 4150
UAE 3 918
Saudi Arabia 18 1729
Upper-middle income Argentina 21 7497
Brazil 14 5581
Chile 5 3270
Malaysia 36 11825
Poland 4 2029
South Africa 11 3252
Turkey 38 4060
Lower-middle income China 110 46751
Philippines 2 1671
Colombia 60 7506
Iran 20 6013
OPT 39 1563
Low income Bangladesh 56 2747
India 97 27458
Pakistan 4 1294
Zimbabwe 3 822
Tanzania 19 1071
Total 661 151619
OPT occupied Palestinian territory, UAE United Arab Emirates, SD standard deviationdifference in prevalence between the poorest and richest
quintiles, with 95% confidence intervals and p-values, to
quantify absolute inequalities. Although this approach is in-
tuitive, we also present the slope index of inequality for each
outcome generated using the same mixed-effects logistic re-
gression framework above. Similar to the concentration
index, this alternative summary measure uses data across
the entire sample, but examines absolute, rather than rela-
tive, inequality [23]. We used Stata v.13 for all analyses [24].
Finally, to identify potential correlates of the magnitude
of wealth-related inequalities we used log-linear regression
trend lines to compare hypertension management out-
comes with economic development of each country,
measured by its 2012 per capita Gross National Product
(in US dollars) [9].
Results
Participant characteristics
Of the 163,397 participants who were enrolled in the PURE
cohort across the 21 study countries and 661 communities,
the personal and household information required for the
current analyses was available from 151,619 participants.
Table 2 shows the characteristics of each country sample.GDP)
nts
No. Rural (%) No. Women (%) Mean Age in years (SD)
2527 (24.3) 5588 (53.7) 53.4 (9.2)
902 (21.7) 2192 (52.8) 52.7 (9.0)
429 (46.7) 653 (71.1) 49.2 (10.2)
186 (10.8) 734 (42.5) 46.5 (9.0)
3897 (52.0) 4607 (61.5) 51.1 (9.9)
1302 (23.3) 3086 (55.3) 52.2 (9.4)
694 (21.2) 2158 (66.0) 51.9 (9.9)
7024 (59.4) 6736 (57.0) 51.3 (9.8)
825 (40.7) 1274 (62.8) 54.6 (9.8)
1766 (54.3) 2213 (68.1) 49.9 (10.3)
1426 (35.1) 2459 (60.6) 50.0 (9.1)
23558 (50.4) 27318 (58.4) 51.0 (10.0)
630 (37.7) 1125 (67.3) 51.8 (9.7)
4036 (53.8) 4819 (64.2) 50.7 (9.8)
2982 (49.6) 3137 (52.2) 48.5 (9.2)
663 (42.4) 780 (49.9) 49.3 (10.0)
1437 (52.3) 1504 (54.8) 46.0 (9.4)
14300 (52.1) 15507 (56.5) 48.7 (10.5)
373 (28.8) 674 (52.1) 47.4 (8.7)
568 (69.1) 590 (71.8) 52.4 (10.1)
420 (39.2) 833 (77.8) 49.9 (11.3)
69945 (46.1) 87987 (58.0) 50.6 (10.0)
, GDP gross domestic product
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women, and the mean age was 50.6 years.
Table 3 shows the percentage of those with hyperten-
sion who were aware, treated and controlled (both lower
threshold definitions). Corresponding figures for the
higher threshold definition are shown in Additional file
6. Nearly half (41%) of participants either self-reported a
history of hypertension and current use of antihyperten-
sive medications, or had an average blood pressure
greater or equal to 140/90 mm Hg. Among those with
hypertension, 47% were aware of their diagnosis; 41% were
being treated; and 13% had their hypertension controlled.
Additional file 7: Figure S1 illustrates patterns of inequal-
ities in adjusted hypertension prevalence (standard lower
threshold definition) by wealth quintile and measured
using concentration indices. Hypertension was signifi-
cantly more common among the richer households in
South Africa, the Philippines and in all low-income coun-
tries. It was more common among poorer households in
Canada, Argentina, Malaysia, Turkey and Iran. Elsewhere
the differences were not significant.
Gaps in the hypertension management pathway within
countries
In all countries, a substantial number of hypertensive
subjects were unaware of their condition (Table 3) and,
of those who were aware, only a proportion was receiv-
ing treatment. For example, in Canada, an estimated
55.2% of patients were aware they had hypertension,
and, among those, 97.9% were treated. Of these, only
45.8% were controlled, revealing that, in total, an esti-
mated 24.8% of hypertensive patients were adequately
managed. In India, the corresponding numbers were
42.1, 79.7, and 40.8%, respectively, so that only 13.7% of
those with hypertension were adequately managed. The
highest level of control was seen in Saudi Arabia, with
the lowest in Tanzania.
Wealth-related inequalities in the hypertension
management pathway within countries
The concentration indices, standardized for age, sex and
urban-rural location (Fig. 1), show that those with hyper-
tension from richer households were significantly more
likely to be aware than those from poorer households in
most lower-income countries. In contrast, awareness
was greater among poorer households in Canada,
Sweden, Argentina, Brazil and Poland, although the
magnitude of these inequalities was relatively small. The
inequalities in hypertension awareness were not statisti-
cally significant in the remaining countries. Treatment
rates were higher among richer households in South
Africa, China, the Philippines, Colombia, Bangladesh,
India, Pakistan and Zimbabwe. They were higher among
poorer households in Canada, Sweden and Poland.Only in Sweden was control better among poorer par-
ticipants. In Saudi Arabia, Malaysia and Turkey there
was no significant inequality in awareness and treatment,
but control was significantly better among richer house-
holds. In China, the Philippines and Colombia, inequal-
ities appear to intensify along each stage of the
management pathway, but many of these trends were
not statistically significant. Further analyses of absolute
inequalities are consistent with these findings, and are
shown by wealth quintile in Table 4 and Additional
file 8: Figure S2, and by slope index of inequality in
Additional file 9: Figure S3.
Hypertension management and economic development
It might be expected that hypertension detection, treat-
ment and control would be better in richer countries,
which can afford strong health systems. Figure 2 ex-
amines the association of hypertension management
outcomes with Gross National Product, with a trend
line based on the log values of the variables. The
lowest levels of awareness were seen in the poorest
countries; yet this is not inevitable as in some poor
countries, levels of awareness were high. Awareness
was lower than expected given national income in
Sweden and South Africa, but was higher than expected
in Brazil, Saudi Arabia, OPT and the Philippines. A
similar pattern is seen with levels of treatment, al-
though there was a particularly large gap between
awareness and treatment in low-income countries and
in China and the Philippines. Control rates were low
everywhere, but again some of the lowest levels are
seen in the poorest countries, with Sweden performing
unexpectedly poorly.
Wealth-related inequalities and economic development
It might also be expected that inequalities would be
greater in poor countries, which tend to have weaker
health systems. Figure 3 summarizes the association
between concentration indices for each hypertension
management outcome and Gross National Product. For
each outcome there is more variation in the levels of in-
equality among poorer countries, with some, such as the
Philippines, having a very unequal distribution on all
measures while others are much more equal. In
Tanzania this is because awareness, treatment and con-
trol are poor for all groups. However, this is not the case
everywhere and some, such as Iran and OPT, achieve
similar outcomes for all. In rich countries the distribu-
tion is fairly similar for all groups or even pro-poor.
Discussion
Summary of findings
We have previously shown that there is sub-optimal
control of hypertension in countries at all economic
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Fig. 1 Magnitude of wealth-related inequalities in hypertension awareness, treatment and control measured by concentration index with 95%
confidence interval
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gaps along the entire management pathway, the
greatest problems in most high- and middle-income
countries lie in awareness and control. Once a pa-
tient is diagnosed, they are very likely to be treated
but not necessarily controlled. In contrast, in most
of the low-income countries there tends to be steady
attrition from awareness through treatment to con-
trol. What this study adds is that the gaps from de-
tection through treatment to control vary among
people with different levels of material resources
within each country and within groups of countries
at similar levels of development. This emphasizes the
importance of country-specific information that can
inform the national policies needed to implement
universal health coverage, now a target in the 2015
Sustainable Development Goals [25].Some countries, such as Iran or OPT, exhibit relatively
equitable outcomes. Others, such as the Philippines,
Colombia, India and Pakistan, do not. However, both
levels and distribution of outcomes are important;
Tanzania and Zimbabwe achieve very poor levels of con-
trol, but for everyone. Finally, Canada, Sweden and
Poland exhibit distributions that are actually pro-poor.
Limitations
Other international comparative studies of hypertension
management outcomes exist [4, 26], but PURE is unique
in its geographical reach, both in including countries at
all levels of development, and in the detail collected on
individuals and the communities they live in. However,
it is subject to a number of limitations. In addition to
the recognized biases associated with using self-reported
data, PURE’s design as a cohort study necessitated
Ta
b
le
4
D
iff
er
en
ce
be
tw
ee
n
th
e
po
or
es
t
(Q
1)
an
d
ric
he
st
(Q
5)
w
ea
lth
qu
in
til
es
in
ad
ju
st
ed
es
tim
at
es
a
fo
r
hy
pe
rt
en
si
on
bu
rd
en
an
d
m
an
ag
em
en
t
in
th
e
PU
RE
co
ho
rt
,b
y
co
un
tr
y
(o
rd
er
ed
by
20
06
G
D
P)
C
ou
nt
ry
H
yp
er
te
ns
io
n
%
of
al
lp
ar
tic
ip
an
ts
H
yp
er
te
ns
io
n
aw
ar
en
es
s
%
of
hy
pe
rt
en
si
ve
pa
rt
ic
ip
an
ts
H
yp
er
te
ns
io
n
tr
ea
tm
en
t
%
of
hy
pe
rt
en
si
ve
pa
rt
ic
ip
an
ts
H
yp
er
te
ns
io
n
co
nt
ro
l
%
of
hy
pe
rt
en
si
ve
pa
rt
ic
ip
an
ts
Q
1
Q
5
D
iff
er
en
ce
[9
5%
C
I]
p-
va
lu
e
Q
1
Q
5
D
iff
er
en
ce
[9
5%
C
I]
p-
va
lu
e
Q
1
Q
5
D
iff
er
en
ce
[9
5%
C
I]
p-
va
lu
e
Q
1
Q
5
D
iff
er
en
ce
[9
5%
C
I]
p-
va
lu
e
C
an
ad
a
38
.5
34
.2
−
4.
3
[-8
.0
–0
.7
]
0.
01
9
58
.6
52
.1
−
6.
5
[-1
2.
5–
0.
6]
0.
03
1
55
.6
51
.8
−
3.
7
[-9
.8
–2
.4
]
0.
22
9
21
.8
24
.9
3.
0
[-2
.0
–8
.0
]
0.
24
0
Sw
ed
en
46
.5
46
.3
−
0.
2
[-5
.4
–5
.0
]
0.
94
1
37
.8
34
.1
−
3.
7
[-1
0.
8–
3.
4]
0.
30
5
34
.1
26
.8
−
7.
3
[-1
4.
1–
0.
5]
0.
03
4
9.
7
6.
9
−
2.
8
[-6
.7
–1
.1
]
0.
16
1
U
A
E
46
.5
50
.7
4.
2
[-7
.3
–1
5.
6]
0.
47
6
45
.1
55
.9
10
.9
[-4
.6
–2
6.
3]
0.
16
8
46
.8
52
.9
6.
1
[-9
.5
–2
1.
6]
0.
44
4
7.
2
12
.2
5.
0
[-3
.9
–1
3.
9]
0.
27
1
Sa
ud
iA
ra
bi
a
28
.2
26
.9
−
1.
3
[-8
.6
–6
.0
]
0.
73
0
70
.2
70
.4
0.
2
[-1
4.
0–
14
.3
]
0.
98
3
68
.4
66
.4
−
2.
0
[-1
6.
7–
12
.7
]
0.
78
8
23
.8
37
.5
13
.8
[0
.2
–2
7.
4]
0.
04
7
A
rg
en
tin
a
51
.2
46
.7
−
4.
6
[-8
.6
–0
.5
]
0.
02
8
57
.9
52
.7
−
5.
2
[-1
0.
5–
0.
2]
0.
06
0
49
.9
49
.3
−
0.
6
[-6
.1
–4
.8
]
0.
81
6
13
.1
12
.5
−
0.
6
[-4
.0
–2
.8
]
0.
73
4
Br
az
il
53
.9
52
.7
−
1.
2
[-6
.2
–3
.7
]
0.
63
4
67
.7
60
.4
−
7.
3
[-1
3.
7–
0.
9]
0.
02
5
67
.1
62
.3
−
4.
8
[-1
1.
7–
2.
0]
0.
16
8
26
.1
22
.2
−
3.
9
[-1
0.
1–
2.
3]
0.
21
3
C
hi
le
45
.2
45
.3
0.
1
[-6
.9
–7
.1
]
0.
98
1
60
.6
60
.0
−
0.
6
[-1
0.
2–
9.
0]
0.
90
2
50
.3
51
.9
1.
6
[-8
.7
–1
1.
9]
0.
75
7
16
.4
19
.0
2.
6
[-4
.6
–9
.8
]
0.
47
3
M
al
ay
si
a
42
.8
42
.7
−
0.
2
[-3
.5
–3
.1
]
0.
92
6
44
.4
51
.0
6.
6
[1
.6
–1
1.
6]
0.
01
0
36
.6
41
.5
4.
9
[0
.0
–9
.8
]
0.
05
2
9.
8
12
.2
2.
5
[-0
.6
–5
.5
]
0.
11
0
Po
la
nd
69
.2
73
.8
4.
7
[-3
.3
–1
2.
6]
0.
24
8
54
.2
46
.0
−
8.
3
[-1
8.
9–
2.
4]
0.
12
8
53
.4
42
.1
−
11
.3
[-2
2.
0–
0.
6]
0.
03
8
7.
3
7.
7
0.
4
[-4
.6
–5
.5
]
0.
86
9
So
ut
h
A
fri
ca
59
.9
59
.3
−
0.
6
[-7
.2
–6
.0
]
0.
85
5
21
.4
34
.1
12
.7
[5
.0
–2
0.
4]
0.
00
1
27
.7
38
.1
10
.4
[2
.6
–1
8.
1]
0.
00
9
2.
0
9.
3
7.
2
[3
.8
–1
0.
7]
0.
00
0
Tu
rk
ey
37
.5
31
.4
−
6.
1
[-1
1.
3–
0.
8]
0.
02
3
56
.3
57
.1
0.
7
[-7
.8
–9
.3
]
0.
86
4
49
.4
50
.4
1.
0
[-7
.6
–9
.6
]
0.
82
0
17
.6
22
.2
4.
5
[-2
.2
–1
1.
2]
0.
18
5
C
hi
na
40
.8
38
.4
−
2.
4
[-4
.3
–0
.6
]
0.
00
9
39
.2
44
.8
5.
7
[2
.8
–8
.5
]
0.
00
0
26
.7
34
.0
7.
3
[4
.7
–9
.9
]
0.
00
0
4.
1
7.
7
3.
6
[2
.2
–4
.9
]
0.
00
0
Ph
ili
pp
in
es
43
.0
58
.6
15
.6
[4
.1
–2
7.
1]
0.
00
8
44
.7
69
.7
25
.0
[9
.1
–4
0.
9]
0.
00
2
34
.1
64
.5
30
.4
[1
4.
4–
46
.3
]
0.
00
0
4.
8
26
.1
21
.3
[9
.1
–3
3.
5]
0.
00
1
C
ol
om
bi
a
34
.8
32
.9
−
1.
9
[-6
.6
–2
.7
]
0.
41
6
46
.4
59
.0
12
.6
[4
.5
–2
0.
7]
0.
00
2
38
.4
53
.6
15
.3
[7
.1
–2
3.
4]
0.
00
0
10
.9
19
.5
8.
6
[2
.7
–1
4.
6]
0.
00
4
Ira
n
25
.3
20
.2
−
5.
1
[-9
.2
–1
.0
]
0.
01
5
53
.3
58
.1
4.
8
[-5
.3
–1
4.
8]
0.
35
0
49
.8
55
.9
6.
0
[-4
.2
–1
6.
2]
0.
24
6
16
.0
18
.2
2.
2
[-5
.0
–9
.3
]
0.
55
4
O
PT
37
.8
33
.7
−
4.
1
[-1
3.
1–
4.
8]
0.
36
8
62
.2
52
.1
−
10
.1
[-2
5.
1–
4.
9]
0.
18
8
60
.0
51
.3
−
8.
7
[-2
3.
5–
6.
1]
0.
25
0
17
.3
13
.3
−
3.
9
[-1
3.
8–
5.
9]
0.
43
1
Ba
ng
la
de
sh
31
.8
52
.0
20
.2
[1
3.
8–
26
.6
]
0.
00
0
14
.0
24
.9
10
.9
[2
.0
–1
9.
8]
0.
01
6
8.
8
21
.2
12
.5
[4
.5
–2
0.
4]
0.
00
2
1.
7
4.
9
3.
2
[-0
.6
–7
.0
]
0.
10
1
In
di
a
13
.6
35
.4
21
.9
[1
9.
2–
24
.6
]
0.
00
0
27
.2
48
.0
20
.8
[1
6.
3–
25
.3
]
0.
00
0
20
.9
43
.0
22
.1
[1
7.
7–
26
.6
]
0.
00
0
8.
9
15
.0
6.
1
[3
.2
–9
.1
]
0.
00
0
Pa
ki
st
an
29
.8
31
.7
1.
8
[-1
1.
2–
14
.8
]
0.
78
4
27
.9
56
.2
28
.3
[8
.8
–4
7.
9]
0.
00
5
15
.7
50
.1
34
.4
[1
6.
7–
52
.2
]
0.
00
0
9.
9
26
.2
16
.3
[1
.3
–3
1.
3]
0.
03
3
Zi
m
ba
bw
e
57
.9
64
.3
6.
4
[-1
0.
2–
23
.1
]
0.
44
9
43
.1
51
.1
8.
0
[-1
5.
8–
31
.8
]
0.
51
1
19
.5
25
.8
6.
3
[-1
1.
9–
24
.5
]
0.
49
7
4.
4
8.
0
3.
7
[-6
.6
–1
3.
9]
0.
48
5
Ta
nz
an
ia
+
34
.7
40
.0
5.
3
[-6
.7
-1
7.
2]
0.
38
9
9.
7
5.
1
-4
.5
[-1
3.
7-
4.
7]
0.
33
8
3.
0
3.
9
0.
9
[-5
.7
-7
.5
]
0.
79
0
Q
1
po
or
es
t
w
ea
lth
qu
in
til
e,
Q
5
ric
he
st
w
ea
lth
qu
in
til
e,
U
A
E
U
ni
te
d
A
ra
b
Em
ira
te
s,
O
PT
oc
cu
pi
ed
Pa
le
st
in
ia
n
te
rr
ito
ry
,C
Ic
on
fid
en
ce
in
te
rv
al
.N
ot
e:
a I
nd
ire
ct
ly
st
an
da
rd
iz
ed
fo
r
ag
e
an
d
se
x,
an
d
co
nt
ro
lle
d
fo
r
ur
ba
n-
ru
ra
l
lo
ca
tio
n.
+
A
dj
us
te
d
es
tim
at
es
fo
r
hy
pe
rt
en
si
on
co
nt
ro
lb
y
w
ea
lth
qu
in
til
e
in
Ta
nz
an
ia
co
ul
d
no
t
be
ob
ta
in
ed
du
e
to
th
e
lo
w
nu
m
be
r
of
po
si
tiv
e
ou
tc
om
es
Palafox et al. International Journal for Equity in Health  (2016) 15:199 Page 8 of 14
Fig. 2 Association between outcomes of hypertension awareness, treatment and control, and economic development measured as GNP per
capita (2012 US dollars)
Palafox et al. International Journal for Equity in Health  (2016) 15:199 Page 9 of 14inclusion of subjects in communities who could feasibly
and affordably be followed up over many years. Hence,
the sampling framework in each country was not de-
signed to be nationally representative, and sample sizes
were relatively modest in some countries, such as
Zimbabwe. Whilst analysis of the PURE household
sample has showed good concordance with the national
age, sex, urban/rural, education, and mortality profiles
of the study countries, suggesting that there was no sys-
temic bias in data collection [10], caution is still war-
ranted when interpreting and extrapolating our findings
to national level.
Also, the individual element reported here was
limited to subjects aged 35 to 70, as they are at
highest risk of cardiovascular disease. This meansthat our estimates of hypertension prevalence, its de-
tection, treatment and control will be higher than
those derived from individual surveys of people at
all ages. Some of the most marginalized groups, such
as migrant workers, will also have been missed. As
with all research on inequalities, it is important to
recognize the scope for artefacts where sampling
methods exclude those at the extremes of the distri-
bution, although considerable care was taken when
recruiting communities to achieve representation and
avoid this problem.
The asset-based wealth index, while facilitating compari-
sons across such a diverse range of countries, is only one
approach to measuring inequalities and is subject to cer-
tain limitations. We have also adopted a parsimonious
Fig. 3 Association between concentration indices for hypertension awareness, treatment and control, and economic development measured as
GNP per capita (2012 US dollars)
Palafox et al. International Journal for Equity in Health  (2016) 15:199 Page 10 of 14approach when estimating concentration indices, avoiding
over-adjustment for other variables. Although such vari-
ables may be important determinants of inequalities, ex-
aminations of their effects would be best studied when
limited to a single country or to a few similar ones as any
determinant of inequality is, to some extent, context spe-
cific, such as membership of a particular ethnic group.
Notwithstanding these limitations, the data presented
here provide important new information on the scale
and nature of inequalities at each stage of the hyperten-
sion management pathway, presenting the data by indi-
vidual country rather than in groups within the same
category of economic development. This provides a
much more finely grained picture, highlighting import-
ant differences in otherwise similar countries. This is
critical, given that health policy development takes place
at the national level.Comparisons with other research
Our findings are broadly consistent with the existing,
albeit somewhat fragmentary research, looking prima-
rily at differences in prevalence of hypertension or
adherence to treatment, with few international com-
parative studies and none, to our knowledge, that look
at inequalities using comparable measures, such as the
concentration index. Thus, we found 92% of Canadians
aware of hypertension were being treated, compared
with 82% in the Canadian Community Health Survey
[27]. While the rates of awareness, treatment and con-
trol in Sweden were substantially lower than the other
high-income PURE countries, they were similar to
those in an earlier study that used data from the WHO
MONICA (Multinational MONItoring of trends and
determinants in CArdiovascular disease) Project [28].
In Iran, data from the National Surveillance of Risk
Palafox et al. International Journal for Equity in Health  (2016) 15:199 Page 11 of 14Factors for NCDs also showed a similarly large attrition
in the pathway of hypertensive individuals from detec-
tion through treatment to control (33% treated and
12% controlled, respectively, compared with 51 to 18%
in our study) [29]. A recent paper combined data from
SAGE (WHO Study on global AGEing and adult
health) and COURAGE (Collaborative Research on
Ageing in Europe), with data on hypertension preva-
lence by household wealth [5]. Among the countries in
common with PURE, similar levels of hypertension
awareness and control were reported: in China, 43%
were aware and 8% controlled vs. 42 and 8% in our
study; in India, 38% aware and 14% controlled vs. 42
and 14% in our study; and in South Africa, 38% aware
and 8% controlled vs. 31 and 6% in our study.
Studies examining wealth-related inequalities are
much fewer in number, however the pro-rich inequal-
ities observed for detection and control observed in our
study were consistent with previous findings in China,
India and South Africa [5]; as were other study findings
regarding hypertension treatment rates in Brazil [30],
China [31], Iran [29] and Tanzania [32]. Finally, a re-
cent Canadian study of adults using national data found
no evidence for income-related inequality with respect
to hypertension detection or control [33], while we ob-
served a small, albeit significant, pro-poor distribution
for detection but not control.
Interpretation
The most important message from this study is that
generalizations based on research in a few countries
must be cautious. We describe considerable diversity in
the patterns observed even in countries at similar levels
of development, both at what point on the clinical
pathway the problems are greatest and in how detec-
tion, treatment and control vary by household wealth.
Consequently, further research within individual coun-
tries is needed to understand better how characteristics
of national health systems influence treatment seeking
behavior for hypertension. Studies such as this one can
only be a first step in developing appropriate policies.
Nonetheless, the observed gaps and inequalities still
highlight the importance of ensuring universal access
to affordable, efficient and contextually appropriate
methods to detect hypertension in middle age, and
when detected, to provide continuous access to skilled
health workers and treatment, including medications.
As such, good population-level hypertension control is
unlikely to be achieved unless approaches to universal
health care include mechanisms to ensure access to
both primary care and essential drugs for all.
As alluded to above, further research is being taken
forward within PURE in the form of detailed health
system analyses. Those completed so far revealcomplex pictures relating to both demand for treat-
ment, influenced by cost of drugs and by how hyper-
tension – a chronic, asymptomatic, but hazardous
condition – is conceptualized, and by supply of
trained health professionals and medicines [34, 35].
Other data from the Environmental Profile of a Com-
munity’s Health study (EPOCH), nested within PURE,
also provide insights. Among the upper-middle in-
come countries, treatment rates were highest in Brazil
and Poland, where all pharmacies surveyed in PURE
communities had four common CVD medicines in
stock and the median cost, as a percentage of ability,
to pay was 3 and 1% respectively. On the other hand,
the lowest treatment rates were in Malaysia and South
Africa, where availability was, respectively, 37 and
33% and the cost as a percentage of ability to pay was
9 and 32% [36]. This has clear consequences for
inequalities in treatment and control, particularly as
effective blood pressure control typically requires use
of two or more medicines [37]. Thus, wealth-related
inequality in hypertension control was pro-rich in
Malaysia and South Africa, and in many other lower
middle- and low-income countries. In contrast, it was
relatively equitable in Iran, where access to affordable
medicines is good [38].
Some other observations are possible based on know-
ledge of the health systems involved. In general, the
percentage of participants aware of hypertension and
on treatment tends to be higher in countries with uni-
versal health care, but only if it renders long-term
medication affordable. Universal health care should
also reduce inequalities where levels of coverage are
high. Brazil has implemented wide-ranging healthcare
reforms, including provision of common medications
for free, with one survey finding that over 90% of users
of the public system, the Family Health Strategy, who
were aware of hypertension were taking medicine [39].
Yet, while China has three insurance schemes that also
provide some degree of coverage for most of the popu-
lation, medicines are paid for out of pocket and can be
expensive [40]. In contrast, though India has yet to im-
plement universal health coverage, it has a thriving do-
mestic generics industry with high levels of availability,
but affordability is poor [36].
Conclusion
The burden of hypertension is high in countries at all
levels of development but some are able to deliver better
and more equitable care. However, there is no consistent
pattern. This emphasizes the need for individually tai-
lored national solutions, an approach incorporated
within the World Heart Federation hypertension road-
map [41], which sets out practical steps to improve
hypertension control for all.
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